Daratumumab for immune thrombotic thrombocytopenic purpura.

Van den Berg, Jana; Kremer Hovinga, Johanna A.; Pfleger, Claudia; Hegemann, Inga; Stehle, Gregor Thomas; Holbro, Andreas; Studt, Jan-Dirk (2022). Daratumumab for immune thrombotic thrombocytopenic purpura. Blood advances, 6(3), pp. 993-997. American Society of Hematology 10.1182/bloodadvances.2021005124

Text Daratumumab_for_immune_thrombotic_thrombocytopenic_purpura.pdf - Accepted Version Restricted to registered users only Available under License Publisher holds Copyright. Download (771kB)

Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy. It is caused by a severe ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motifs, 13) deficiency due to circulating autoantibodies, and is associated with significant morbidity and mortality. Current treatment options include plasma exchange, immunosuppression, and caplacizumab. When remission is achieved, the risk of relapse is high, especially in patients with persistent ADAMTS13 deficiency. We report the eradication of persistent ADAMTS13 inhibitory autoantibodies and restoration of normal ADAMTS13 activity using the anti-CD38 antibody daratumumab in two patients with iTTP. One patient had a frequently relapsing course, and the other a treatment-refractory first episode. There were no relevant adverse drug reactions.

Interest & Impact

Downloads

4 since deposited on 12 Oct 2021
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item